Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients

[1]  K. Rezvani,et al.  How I treat high-risk acute myeloid leukemia using pre-emptive adoptive cellular immunotherapy. , 2022, Blood.

[2]  J. Esteve,et al.  Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia , 2021, Bone Marrow Transplantation.

[3]  J. Ferrara,et al.  New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD) , 2021, Expert opinion on therapeutic targets.

[4]  P. Chevallier,et al.  Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high risk acute myeloid leukemia or myelodysplastic syndrome. , 2021, Transplantation and cellular therapy.

[5]  G. Kobbe,et al.  Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group , 2020, Annals of Hematology.

[6]  M. Schumacher,et al.  Relapse- and immunosuppression-free survival after hematopoietic stem-cell transplantation: How can we assess treatment success for complex time-to-event endpoints? , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  M. Perales,et al.  Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myeloid Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  N. Kröger,et al.  Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT , 2019, Journal of Hematology & Oncology.

[9]  R. Larson,et al.  Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  L. Kanz,et al.  G‐CSF administration prior to donor lymphocyte apheresis promotes anti‐leukaemic effects in allogeneic HCT patients , 2019, British journal of haematology.

[11]  J. Esteve,et al.  Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT , 2018, British journal of haematology.

[12]  J. Wagner,et al.  Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allotransplantation. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  M. Horowitz,et al.  Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. , 2019, JAMA oncology.

[14]  N. Kröger,et al.  The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies , 2019 .

[15]  J. Esteve,et al.  Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation , 2018, Bone Marrow Transplantation.

[16]  B. Sandmaier,et al.  Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  M. Solh,et al.  Current Graft-versus-Host Disease-Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  J. Esteve,et al.  Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) , 2015, Journal of Hematology & Oncology.

[19]  J. Oldenburg,et al.  Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products. , 2016, Cytotherapy.

[20]  H. Putter,et al.  Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion , 2016, Haematologica.

[21]  M. Norkin,et al.  Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  D. Blaise,et al.  Hematopoietic stem cell transplantation for patients with AML in first complete remission. , 2016, Blood.

[23]  I. Jedema,et al.  Allo‐reactive T cells for the treatment of hematological malignancies , 2015, Molecular oncology.

[24]  M. Bishop,et al.  Analysis of the recovery of cryopreserved and thawed CD34+ and CD3+ cells collected for hematopoietic transplantation , 2014, Transfusion.

[25]  H. Veelken,et al.  Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation , 2014, Haematologica.

[26]  M. Norkin,et al.  Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: Impact of tyrosine kinase inhibitor and minimal residual disease , 2013, Leukemia.

[27]  E. Waller,et al.  Finding the sweet spot for donor lymphocyte infusions. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  J. Goldberg,et al.  T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  A. Spyridonidis,et al.  High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  J. Falkenburg,et al.  Alloreactive effector T cells require the local formation of a proinflammatory environment to allow crosstalk and high avidity interaction with nonhematopoietic tissues to induce GVHD reactivity. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  Alan M. Miller,et al.  Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  D. Blaise,et al.  Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a ‘donor’ versus ‘no donor’ comparison , 2009, Leukemia.

[33]  B. Dörken,et al.  A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation , 2008, Bone Marrow Transplantation.

[34]  J. Falkenburg,et al.  Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath ‘in the bag’ as T-cell depletion: the Leiden experience , 2006, Bone Marrow Transplantation.

[35]  R. Storb,et al.  Duration of immunosuppressive treatment for chronic graft-versus-host disease. , 2004, Blood.

[36]  M. Flowers,et al.  Chronic graft-versus-host disease. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  J. Bourhis,et al.  Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. , 2003, Blood.

[38]  C. Fegan,et al.  T‐cell depletion with Campath‐1H ‘in the bag’ for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft‐versus‐host disease, rapid immune constitution and improved survival , 2003, British journal of haematology.

[39]  F. Preijers,et al.  Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions , 2001, Leukemia.

[40]  M. Shlomchik,et al.  Prevention of graft versus host disease by inactivation of host antigen-presenting cells. , 1999, Science.